Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.

Hamm CA, Moran D, Rao K, Trusk PB, Pry K, Sausen M, Jones S, Velculescu VE, Cristofanilli M, Bacus S.

Mol Cancer Ther. 2016 Jul;15(7):1746-56. doi: 10.1158/1535-7163.MCT-15-0353. Epub 2016 Apr 19.

2.

Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.

Doherty KR, Talbert DR, Trusk PB, Moran DM, Shell SA, Bacus S.

Toxicol Appl Pharmacol. 2015 May 15;285(1):51-60. doi: 10.1016/j.taap.2015.03.008. Epub 2015 Apr 2.

PMID:
25841593
3.

A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.

Talbert DR, Doherty KR, Trusk PB, Moran DM, Shell SA, Bacus S.

Toxicol Sci. 2015 Jan;143(1):147-55. doi: 10.1093/toxsci/kfu215. Epub 2014 Oct 10.

PMID:
25304212
4.

KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.

Moran DM, Trusk PB, Pry K, Paz K, Sidransky D, Bacus SS.

Mol Cancer Ther. 2014 Jun;13(6):1611-24. doi: 10.1158/1535-7163.MCT-13-0649. Epub 2014 Mar 31.

5.

Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.

Doherty KR, Wappel RL, Talbert DR, Trusk PB, Moran DM, Kramer JW, Brown AM, Shell SA, Bacus S.

Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55. doi: 10.1016/j.taap.2013.04.027. Epub 2013 May 21.

PMID:
23707608
6.

Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.

Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL, Bacus SS.

Cell Cycle. 2008 Jun 15;7(12):1769-75. Epub 2008 Jun 30.

PMID:
18594201
7.

A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.

Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, Trusk P, Lyass A, Rechavi G, Spector NL, Lo SH, Schmitt F, Bacus SS, Yarden Y.

Nat Cell Biol. 2007 Aug;9(8):961-9. Epub 2007 Jul 22.

PMID:
17643115
8.

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells.

Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10607-12. Epub 2007 Jun 7.

9.

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800. Epub 2006 May 8.

Supplemental Content

Support Center